Autoimmune bullous dermatoses.
ELISA
Pemphigoid
autoantibodies
guidelines
immunofluorescence
mouse model
pemphigus
Journal
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
ISSN: 1610-0387
Titre abrégé: J Dtsch Dermatol Ges
Pays: Germany
ID NLM: 101164708
Informations de publication
Date de publication:
04 2023
04 2023
Historique:
received:
09
01
2023
accepted:
07
02
2023
medline:
19
4
2023
entrez:
18
4
2023
pubmed:
19
4
2023
Statut:
ppublish
Résumé
Autoimmune bullous dermatoses (AIBD) are a heterogeneous group of about a dozen diseases characterized clinically by erosions and blisters and immunopathologically by autoantibodies against structural proteins of the skin or transglutaminase 2/3. The diagnosis of AIBD has made tremendous progress in the last decade due to the availability of standardized serological assays that, knowing the clinical picture, allow the diagnosis in the vast majority of patients. The development of various in vitro and in vivo models of the most common AIBD, namely, bullous pemphigoid, pemphigus vulgaris, mucous membrane pemphigoid, and the rare epidermolysis bullosa acquisita, allows identification of key molecules and inflammatory pathways as well as preclinical evaluation of the effect of new anti-inflammatory agents. The approval of rituximab for moderate and severe pemphigus vulgaris and the development of national and international guidelines for the most common AIBD have considerably advanced the care of these patients. Nevertheless, the limited therapeutic armamentarium is the main challenge for the management of AIBD. Several phase II and III randomized controlled clinical trials provide hope for new, effective, and safe therapeutic options in the coming years. This review summarizes the epidemiology, clinic, diagnosis, pathophysiology, and therapy of AIBD and gives an outlook on both current diagnostic and therapeutic needs as well as future developments.
Substances chimiques
Autoantibodies
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
405-412Informations de copyright
© 2023 The Authors. Journal der Deutschen Dermatologischen Gesellschaft published by John Wiley & Sons Ltd on behalf of Deutsche Dermatologische Gesellschaft.
Références
Schmidt E, Zillikens D. Pemphigoid diseases. Lancet. 2013;381:320-332.
Schmidt E, Kasperkiewicz M, Joly P. Pemphigus. Lancet. 2019;394:882-894.
Kasperkiewicz M, Ellebrecht CT, Takahashi H, et al. Pemphigus. Nat Rev Dis Primers. 2017;3:17026.
Pollmann R, Schmidt T, Eming R, et al. Pemphigus: a Comprehensive Review on Pathogenesis, Clinical Presentation and Novel Therapeutic Approaches. Clin Rev Allergy Immunol. 2018;54:1-25.
Beek NV, Zillikens D, Schmidt E. Bullous Autoimmune dermatoses - clinical features, diagnostic evaluation, and treatment options. Dtsch Arztebl Int. 2021;118:413-420.
Kridin K. Pemphigus group: overview, epidemiology, mortality, and comorbidities. Immunol Res. 2018;66:255-270.
Bertram F, Brocker EB, Zillikens D, et al. Prospective analysis of the incidence of autoimmune bullous disorders in Lower Franconia, Germany. J Dtsch Dermatol Ges. 2009;7:434-440.
van Beek N, Weidinger A, Schneider SW, et al. Incidence of pemphigoid diseases in Northern Germany in 2016 - first data from the Schleswig-Holstein Registry of Autoimmune Bullous Diseases. J Eur Acad Dermatol Venereol. 2021;35:1197-1202.
van Beek N, Schmidt E. Autoimmune bullous diseases. In: Höger P, Kinsler V, Yan A (Eds). Harper's Textbook of Pediatric Dermatology, chapter 73, 4th edition. Wiley-Blackwell, Chichester, 2020:868-897.
Hübner F, König IR, Holtsche MM, et al. Prevalence and age distribution of pemphigus and pemphigoid diseases among paediatric patients in Germany. J Eur Acad Dermatol Venereol. 2020;34:2600-2605.
Sarig O, Bercovici S, Zoller L, et al. Population-specific association between a polymorphic variant in ST18, encoding a pro-apoptotic molecule, and pemphigus vulgaris. J Invest Dermatol. 2012;132:1798-1805.
Schwarm C, Gola D, Holtsche MM, et al. Identification of two novel bullous pemphigoid- associated alleles, HLA-DQA1*05:05 and -DRB1*07:01, in Germans. Orphanet J Rare Dis. 2021;16(1):228.
Velasco-Tamariz V, Calleja-Algarra A, Palencia-Pérez SI, et al. Paraneoplastic pemphigus associated with Castleman's disease and thyroid carcinoma with anti-BP180, BP230 and antidesmocollin autoantibodies. J Dtsch Dermatol Ges. 2021;19:289-291.
Schmidt E, Groves R. Immunobullous diseases. In: Griffith C, Barker J, Chalmers, Bleiker T, Creamer D (Eds). Rook's Textbook of Dermatology, part 3, chapter 50, 9th edition. Wiley-Blackwell, Chichester, 2016:1-56.
Meijer JM, Diercks GF, Schmidt E, et al. Laboratory diagnosis and clinical profile of anti-p200 pemphigoid. JAMA Dermatol. 2016;152:897-904.
Hofmann SC, Günther C, Böckle BC, et al. S2k Guideline for the diagnosis and treatment of mucous membrane pemphigoid. J Dtsch Dermatol Ges. 2022;20:1530-1350.
Rashid H, Lamberts A, Borradori L, et al. European guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology - Part I. J Eur Acad Dermatol Venereol. 2021;35:1750-1764.
Holtsche MM, Zillikens D, Schmidt E. Mucous membrane pemphigoid. Hautarzt. 2018;69:67-83.
Du G, Patzelt S, van Beek N, et al. Mucous membrane pemphigoid. Autoimmun Rev. 2022;21:103036.
Vorobyev A, Ludwig RJ, Schmidt E. Clinical features and diagnosis of epidermolysis bullosa acquisita. Expert Rev Clin Immunol. 2017;13:157-169.
Görög A, Antiga E, Caproni M, et al. S2k guidelines (consensus statement) for diagnosis and therapy of dermatitis herpetiformis initiated by the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol. 2021;35:1251-1277.
Martin E, Mauer I, Malzahn U, et al. Comorbid diseases among bullous pemphigoid patients in Germany: new insights from a case-control study. J Dtsch Dermatol Ges. 2022;20:798-805.
Huang IH, Wu PC, Liu CW, et al. Association between bullous pemphigoid and psychiatric disorders: A systematic review and meta-analysis. J Dtsch Dermatol Ges. 2022;20:1305-1312.
Bech R, Kibsgaard L, Vestergaard C. Comorbidities and treatment strategies in bullous pemphigoid: an appraisal of the existing litterature. Front med (Lausanne). 2018;5:238.
Schulze F, Neumann K, Recke A, et al. Malignancies in pemphigus and pemphigoid diseases. J Invest Dermatol. 2015;135:1445-1447.
Goletz S, Giurdanella F, Holtsche MM, et al. Comparison of two diagnostic assays for anti-laminin 332 mucous membrane pemphigoid. Front Immunol. 2021;12:773720.
van Beek N, Kridin K, Bühler E, et al. Evaluation of site- and autoantigen-specific characteristics of mucous membrane pemphigoid. JAMA Dermatol. 2022;158:84-89.
Bardazzi F, Rucci P, Rosa S, et al. Comorbid diseases associated with pemphigus: a case-control study. J Dtsch Dermatol Ges. 2021;19:1613-1609.
Kridin K, Schmidt E. Epidemiology of Pemphigus. JID innovations. 2021;1:100004.
Liu SD, Chen WT, Chi CC. Association between medication use and bullous pemphigoid: a systematic review and meta-analysis. JAMA Dermatol. 2020;156:891-900.
Schmidt E, Sticherling M, Sárdy M, et al. S2k guidelines for the treatment of pemphigus vulgaris/foliaceus and bullous pemphigoid: 2019 update. J Dtsch Dermatol Ges. 2020;18:516-526.
Spindler V, Eming R, Schmidt E, et al. Mechanisms causing loss of keratinocyte cohesion in pemphigus. J Invest Dermatol. 2018;138:32-37.
Schmitt T, Waschke J. Autoantibody-specific signalling in pemphigus. Front Med (Lausanne). 2021;8:701809.
Heppe EN, Tofern S, Schulze FS, et al. Experimental laminin 332 mucous membrane pemphigoid critically involves C5aR1 and reflects clinical and immunopathological characteristics of the human disease. J Invest Dermatol. 2017;137:1709-1718.
Sitaru C, Mihai S, Otto C, et al. Induction of dermal-epidermal separation in mice by passive transfer of antibodies specific to type VII collagen. J Clin Invest. 2005;115:870-878.
Sitaru C, Schmidt E, Petermann S, et al. Autoantibodies to bullous pemphigoid antigen 180 induce dermal-epidermal separation in cryosections of human skin. J Invest Dermatol. 2002;118:664-671.
Chakievska L, Holtsche MM, Kunstner A, et al. IL-17A is functionally relevant and a potential therapeutic target in bullous pemphigoid. J Autoimmun. 2019;96:104-112.
Karsten CM, Pandey MK, Figge J, et al. Anti-inflammatory activity of IgG1 mediated by Fc galactosylation and association of FcgammaRIIB and dectin-1. Nat Med. 2012;18:1401-1406.
Sezin T, Krajewski M, Wutkowski A, et al. The Leukotriene B4 and its receptor BLT1 act as critical drivers of neutrophil recruitment in murine bullous pemphigoid-like epidermolysis bullosa acquisita. J Invest Dermatol. 2017;137:1104-1113.
Liu Z, Zhou X, Shapiro SD, et al. The serpin alpha1-proteinase inhibitor is a critical substrate for gelatinase B/MMP-9 in vivo. Cell. 2000;102:647-655.
Meijer JM, Atefi I, Diercks GFH, et al. Serration pattern analysis for differentiating epidermolysis bullosa acquisita from other pemphigoid diseases. J Am Acad Dermatol. 2018;78:754-9 e6.
van Beek N, Zillikens D, Schmidt E. Diagnosis of autoimmune bullous diseases. J Dtsch Dermatol Ges. 2018;16:1077-1091.
Pieper J, Pollmann R, Eming R, et al. Disease progression and response to therapy in pemphigus based on a registry. J Dtsch Dermatol Ges. 2022;20:461-467.
Schmidt E, Goebeler M, Hertl M, et al. S2k guideline for the diagnosis of pemphigus vulgaris/foliaceus and bullous pemphigoid. J Dtsch Dermatol Ges. 2015;13:713-727.
Schmidt E, Rashid H, Marzano AV, et al. European Guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology - Part II. J Eur Acad Dermatol Venereol. 2021;35:1926-1948.
Borradori L, Van Beek N, Feliciani C, et al. Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol. 2022;36:1689-1704.
Bieber K, Kridin K, Emtenani S, et al. Milestones in personalized medicine in pemphigus and pemphigoid. Front Immunol. 2020;11:591971.
Hocke J, Krauth J, Krause C, et al. Computer-aided classification of indirect immunofluorescence patterns on esophagus and split skin for the detection of autoimmune dermatoses. Front Immunol. 2023;14:1111172.
Burmester IAK, Flaswinkel S, Thies CS, et al. Identification of novel therapeutic targets for blocking acantholysis in pemphigus. Br J Pharmacol. 2020;177:5114-5130.
Kasprick A, Hofrichter M, Smith B, et al. Treatment with anti-neonatal Fc receptor (FcRn) antibody ameliorates experimental epidermolysis bullosa acquisita in mice. Br J Pharmacol. 2020;177:2381-2392.
Murthy S, Schilf P, Patzelt S, et al. Dapsone suppresses disease in preclinical murine models of pemphigoid diseases. J Invest Dermatol. 2021;141:2587-2595e2.
Ghorbanalipoor S, Emtenani S, Parker M, et al. Cutaneous kinase activity correlates with treatment outcomes following PI3K delta inhibition in mice with experimental pemphigoid diseases. Front Immunol. 2022;13:865241.